1065074-89-6

Basic information

• Product Name: 4-(3-Bromo-5-nitropyridin-2-yl)morpholine
• Synonyms: 4-(3-Bromo-5-nitropyridin-2-yl)morpholine;4-(3-Bromo-5-nitro-2-pyridinyl)morpholine
• CAS NO: 1065074-89-6
• Molecular Formula: C9H10BrN3O3
• Molecular Weight: 288
• Mol File: 1065074-89-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(3-Bromo-5-nitropyridin-2-yl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Bromo-5-nitropyridin-2-yl)morpholine(1065074-89-6)
• EPA Substance Registry System: 4-(3-Bromo-5-nitropyridin-2-yl)morpholine(1065074-89-6)

Safety Data

• Hazardous Substances Data: 1065074-89-6(Hazardous Substances Data)

Usage

General Description

4-(3-Bromo-5-nitropyridin-2-yl)morpholine is a chemical compound with the molecular formula C9H9BrN3O3. It is a heterocyclic compound containing a morpholine ring and a pyridine ring, both of which are functionalized with a bromine atom and a nitro group, respectively. 4-(3-Bromo-5-nitropyridin-2-yl)morpholine is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is known for its versatile reactivity and can participate in a variety of chemical reactions, such as nucleophilic substitution, cycloaddition, and metal-catalyzed coupling reactions. It is important to handle this compound with care, as it may pose health or environmental hazards if not used and disposed of properly.

Upstream product

• 110-91-8 morpholine 
• 5470-17-7 3-bromo-2-chloro-5-nitropyridine 

Downstream Products

• 1215932-56-1 5-bromo-6-morpholinopyridin-3-amine 
• 353285-86-6 4-(3-methyl-5-nitropyridin-2-yl)morpholine 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF

The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.